Фармакогенетические аспекты пероральной сахароснижающей терапии. Фенотипы «ответа» и «провала»
Аннотация
Список литературы
1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой. Издание шестое. М.: ФГБУ ЭНЦ, 2013: 120.
2. Кравчук Е.Н. Применение метформина при сочетании ишемической болезни сердца и сахарного диабета 2-го типа: механизмы действия и клиническая эффективность. Е.Н. Кравчук, М.М. Галагудза. Сахарный диабет, 2013, 1: 5-14.
3. HeritabiLity of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Zhou K., Donnelly L., Yang J. et al. The Lancet. Diabetes and Endocrinology, 2014, 2(6): 481-487. doi: 10.1016/S2213-8587(14)70050-6. Epub 2014 Mar 19.
4. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Goswami S at al. Clin Pharmacol Ther., 2014, 96(3): P. 370379. doi: 10.1038/clpt.2014.109. Epub 2014 May 22.
5. Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here? (Review). Emami-Riedmaier A. [et al.]. J Intern Med., 2015, 277: 235-247.
6. Wang XL, Mahaney MC, Sim AS et al. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler. Thromb. Vasc. Biol, 1997, 17: 3147-3153.
7. Nakayama M, Yasue H, Yoshimura M et al. T-786 C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation, 1999, 99: 2864-2870.
8. T(-786)^C polymorphism of the endothelial nitric oxide synthase gene is associated with insulin resistance in patients with ischemic or non ischemic cardiomyopathy. C. Vecoli, M.G. Andreassi, R. Liga [et al.]. BMC Med Genet., 2012, 2(13): 92. doi: 10.1186/1471-2350-13-92.
9. eNOS polymorphism associated with metabolic syndrome in children and adolescents. J.A. Miranda, V.A. Belo, D.C. Souza-Costa. Mol Cell Biochem., 2013, 372(1-2): 155-60. doi: 10.1007/ s11010-012-1456-y.
10. Roy D, Perreault M and Marette A. Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. AJP-Endocrinology and Metabolism, 1998, 274(4): 692-699.
11. Variants of endothelial nitric oxide synthase gene are associated with components of metabolic syndrome in an Arab population. K.M. Alkharfy, N.M. Al-Daghri, O.S. Al-Attas et al. Endocr J., 2012, 59(3): 253-263. Epub 2012 Jan 12.
12. Tallapragada DS. Long standing partnership between insulin resistance and endothelial dysfunction: Role of metabolic memory. D.S. Tallapragada, P.A. Karpe, K.Tikoo. Br J Pharmacol., 2015, Mar 30. doi: 10.1111/ bph.13145. [Epub ahead of print].
13. Alteration of mitochondrial function and insulin sensitivity in primary mouse skeletal muscle cells isolated from transgenic and knockout mice: role of OGG1. L.V. Yuzefovych, A.M. Schuler, J. Chen et al. Endocrinology, 2013, 154(8): 2640-2649. doi: 10.1210/en.2013-1076.
14. The hOGG1 Ser326Cys gene polymorphism is associated with decreased insulin sensitivity in subjects with normal glucose tolerance. C.L. Wang, M.C. Hsieh, S.C. Hsin. Journal of Human Genetics, 2006, 51(2): 124-128. Epub 2005 Dec 7,
15. Associations between hOGG1 Ser326Cys polymorphism and increased body mass index and fasting glucose level in the Japanese general population. M. Hara, K. Nakamura, H. Nanri [et al.]. Journal of Epidemiology, 2014, 24(5): 379-384.
16. Гормонально-метаболические и генетические маркеры чувствительности к метформину при диабете и раке: предсказание и реальность. Берштейн Л.М., Васильев Д.А., Иевлева А.Г. и др. Сахарный диабет, 2014, 1: 21-28.
17. Bonfigli AR. The p53 codon 72 (Arg72Pro) polymorphism is associated with the degree of insulin resistance in type 2 diabetic subjects: a cross-sectional study. A.R. Bonfigli. Acta Diabetologia, 2013, 50(3): 429-436.
18. Burgdorf KS. Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans. K.S. Burgdorf. PLoS One, 2011, 20(6): e15813. doi: 10.1371/journal. pone.0015813 [Электронный ресурс]. -Режим доступа: http//www.ncbi.nlm.nih.gov/ pmc/articles/PMC3024396/ (дата обращения 20.11.2013).
19. Gaulton KJ. Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. K.J. Gaulton. Diabetes., 2008, 11: 3136-3144.
20. Gloria-Bottini F. Is there a role of p53 codon 72 polymorphism in the susceptibility to type 2 diabetes in overweight subjects? A study in patients with cardiovascular diseases. F. Gloria-Bottini. Diabetes Research and Clinical Practice, 2011, 3: P. 4-7.
21. Tornovsky-Babeay S. Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in p cells. S. Tornovsky-Babeay et al. Cell metabolism., 2014, 19(1): 109-121.
22. Ou L. Association between polymorphisms in RAPGEF1, TP53, NRF1 and type 2 diabetes in Chinese Han population. L. Ou et al. Diabetes Research and Clinical Practice, 2011, 91(2): 171-176.
23. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Z. Luo, M. Zang, W.Guo. Future Oncology, 2010, 6(3). Vol. 457-470. doi: 10.2217/ fon.09.174.
24. Dincer Y. Serum levels of p53 and cytochrome c in subjects with type 2 diabetes and impaired glucose tolerance. Y Dincer. Clin Invest Med., 2009, 32(4): 266-270.
25. Minamino T. A crucial role for adipose tissue p53 in the regulation of insulin resistance. T. Minamino et al. Nature Med., 2009, 15(9): 1082-1087.
Для цитирования:
Сорокина Ю.А. Фармакогенетические аспекты пероральной сахароснижающей терапии. Фенотипы «ответа» и «провала». Медицинский Совет. 2015;(8):82-85. https://doi.org/10.21518/2079-701X-2015-8-82-85
For citation:
Sorokina Y.A. Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypes. Meditsinskiy sovet = Medical Council. 2015;(8):82-85. (In Russ.) https://doi.org/10.21518/2079-701X-2015-8-82-85